Latest News

nov 2023

What If Psychedelics’ Hallucinations Are Just a Side Effect?

july 2023

Recognizing inspiring achievements from 2023

sept 2022

Taking the tripping out of psychedelic medicine

sept 2022

Ketamine, psilocybin and ecstasy are coming to the medicine cabinet

july 2023

The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"

june 2023

Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for Novel Compound DLX-001

may 2023

Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

june 2023

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

feb 2023

Pioneering Delix Therapeutics Study Published in 'Science' Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity

feb 2023

Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability

september 2022

Nature Biotechnology’s academic spinouts 2021

september 2022

Nature Biotechnology Selects Delix Therapeutics as a Leading Biotech Start-Up

september 2022

Delix Therapeutics Expands World-Class Team with First Head of R&D

september 2022

Delix Therapeutics and Pfizer UK Recognized as Gender Equity Champions for Women in the Workplace by Healthcare Businesswomen's Association

august 2022

Get Ready for the Magic Mushroom Pill

july 2022

Accessibility Is Key for the Psychedelic Revolution

july 2022

Taking the Magic Out of Magic Mushrooms

march 2022

Drug companies are investing big in psychedelics, but can they engineer out the trip?

january 2022

Delix Therapeutics Closes $30 Million Convertible Note Financing, Enters $10 Million Strategic Credit Facility Option in Partnership with Comerica Bank

january 2022

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of